BG
PTGX icon

Bellevue Group’s Protagonist Therapeutics PTGX Stock Holding History

Bellevue Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.52M Sell
14,447
-2,096
-13% -$186K 0.04% 86
2025
Q4 		$1.44M Sell
16,543
-4,038
-20% -$331K 0.03% 104
2025
Q3 		$1.37M Buy
20,581
+1,109
+6% +$63K 0.03% 101
2025
Q2 		$1.08M Buy
19,472
+1,850
+10% +$88.8K 0.02% 103
2025
Q1 		$852K Sell
17,622
-6,096
-26% -$255K 0.02% 109
2024
Q4 		$916K Buy
23,718
+11,372
+92% +$496K 0.02% 119
2024
Q3 		$556K Sell
12,346
-2,800
-18% -$113K 0.01% 126
2024
Q2 		$525K Sell
15,146
-4,000
-21% -$117K 0.01% 128
2024
Q1 		$554K Sell
19,146
-10,854
-36% -$295K 0.01% 127
2023
Q4 		$688K Hold
30,000
– – 0.01% 127
2023
Q3 		$500K Buy
+30,000
New +$582K 0.01% 141

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Bellevue Group's PTGX Position: Q1 2026 in Review

Bellevue Group reduced its Protagonist Therapeutics (PTGX) stake by 13% in Q1 2026, selling an estimated $186K and leaving 14,447 shares worth $1.52M. The position accounts for 0.04% of the portfolio, ranked #86.

Bellevue Group first reported a position in PTGX in Q3 2023 and has held it in 11 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Bellevue Group held 14,447 shares of Protagonist Therapeutics worth $1.52M as of Q1 2026.
  • Bellevue Group sold 2,096 Protagonist Therapeutics shares in Q1 2026, an estimated $186K.
  • Protagonist Therapeutics made up 0.04% of Bellevue Group's portfolio in Q1 2026, its #86 holding.
  • Bellevue Group first reported a position in Protagonist Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.